Key terms
About ABUS
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABUS news
Yesterday
8:11am ET
Arbutus Biopharma CSO Sets Retirement Date
Yesterday
8:08am ET
Arbutus Biopharma Showcases Promising Q1 Results
Yesterday
7:42am ET
Arbutus Biopharma Announces Chief Scientific Officer’s Retirement
Apr 26
12:45pm ET
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Apr 26
4:55am ET
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Apr 18
8:19am ET
Arbutus Biopharma Announces Q1 2024 Financial Update
Apr 17
2:00pm ET
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Apr 05
10:40am ET
Biotech Alert: Searches spiking for these stocks today
Apr 04
10:07am ET
Arbutus Biopharma Wins Favorable Ruling Against Moderna
Apr 04
8:38am ET
Arbutus ‘pleased’ with claim construction ruling in patent infringement suit
Apr 03
3:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
Apr 03
3:05pm ET
Moderna could owe $1B-$3B in royalties, says Jefferies
Apr 03
2:02pm ET
Roivant, Arbutus higher after ruling on COVID patent order
Apr 03
1:56pm ET
Jefferies sees Roivant rallying 5%-10% on today’s COVID patent order
Mar 25
4:55am ET
Arbutus Biopharma management to meet virtually with JMP Securities
Mar 20
5:20pm ET
Arbutus Biopharma management to meet virtually with JMP Securities
Mar 08
8:07am ET
Arbutus Biopharma Showcases at Investor Conferences
Mar 05
1:23am ET
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
Mar 01
6:26am ET
Arbutus Biopharma price target lowered to $5 from $6 at H.C. Wainwright
Feb 29
1:55pm ET
Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects
Feb 29
8:19am ET
Arbutus Biopharma Anticipates Key 2024 Milestones
Feb 29
7:33am ET
Arbutus Biopharma reports FY23 EPS (44c), consensus (45c)
Feb 12
11:09am ET
Biotech Alert: Searches spiking for these stocks today
Feb 08
1:05pm ET
Jefferies ‘encouraged thus far’ by Arbutus patent hearing
No recent press releases are available for ABUS
ABUS Financials
Key terms
Ad Feedback
ABUS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABUS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range